fbpx

Media | Nutent Therapeutics



EFFECTIVE, HIGH-QUALITY CURCUMIN ENTERS HEALTH MARKETPLACE


Joint Venture Brings to Market Anti-aging Products Based on Breakthrough Data

BOCA RATON, Fla., May 01, 2019 (GLOBE NEWSWIRE) — Rejuvalan, LLC today announced its launch and its mission to bring readily available, scientifically validated anti-aging products to market. The initiative is driven by data which shows how Rejuvalan’s products can change cells from older people in such a way as to copy the biology of rare species that are resistant to aging. Beyond this, the data also showed that impaired capacity caused by aging was reversed in unique experimental systems, including measures of mental capacity, anxiety and movement. The data was presented at the world’s largest anti-aging conference, Undoing Aging 2019, and a patent has been filed.

…view full article


VOLT03 by Nutent Therapeutics Delivers Pharmaceutical-grade Curcumin with Enhanced Absorption

BOCA RATON, Fla., July 05, 2018 (GLOBE NEWSWIRE) — The first highly purified and well-regulated pharmaceutical-grade curcumin, the most widely-studied plant-derived medicinal chemical in modern science, is now commercially available. Seeing a need for a purer, more effectively absorbing curcumin, Nutent Therapeutics developed, tested and launched VOLT03.

The active ingredient in the turmeric plant (curcuma longa), curcumin is a natural anti-inflammatory and antioxidant shown to improve brain function. It has also been shown to lower the risk of heart disease, help prevent and possibly aid in cancer treatment, provide relief for patients with arthritis and possibly help in the prevention and treatment of Alzheimer’s disease.

…view full article





Nutent Therapeutics was selected to present at the Nutrition Capital Network’s Investor Meeting

Nutent Therapeutics has been selected to present at the Natural Products Canada (NPC) Investor Meeting on September 18-19, 2019 in Toronto, Ontario. The NPC selected only 20 companies across Canada and Nutent was selected based on the approval of Volt03 by Health Canada and the subsequent customer value it possesses. Richard Becker, Nutent’s CEO, will represent and present for the company.


Top

Subscribe to the Nutent Therapeutics Newsletter and receive a discount on your first order